Bon Natural Life (BON) Competitors $2.10 +0.70 (+50.00%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$1.86 -0.24 (-11.29%) As of 08:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock BON vs. FNCH, SLGL, OVID, QTTB, LGVN, NAII, CGTX, DRRX, ELEV, and CMMBShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Finch Therapeutics Group (FNCH), Sol-Gel Technologies (SLGL), Ovid Therapeutics (OVID), Q32 Bio (QTTB), Longeveron (LGVN), Natural Alternatives International (NAII), Cognition Therapeutics (CGTX), DURECT (DRRX), Elevation Oncology (ELEV), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Finch Therapeutics Group Sol-Gel Technologies Ovid Therapeutics Q32 Bio Longeveron Natural Alternatives International Cognition Therapeutics DURECT Elevation Oncology Chemomab Therapeutics Finch Therapeutics Group (NASDAQ:FNCH) and Bon Natural Life (NYSE:BON) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership. Does the MarketBeat Community believe in FNCH or BON? Finch Therapeutics Group received 10 more outperform votes than Bon Natural Life when rated by MarketBeat users. CompanyUnderperformOutperformFinch Therapeutics GroupOutperform Votes1052.63% Underperform Votes947.37% Bon Natural LifeN/AN/A Does the media refer more to FNCH or BON? In the previous week, Bon Natural Life had 4 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 4 mentions for Bon Natural Life and 0 mentions for Finch Therapeutics Group. Bon Natural Life's average media sentiment score of 0.67 beat Finch Therapeutics Group's score of 0.00 indicating that Bon Natural Life is being referred to more favorably in the news media. Company Overall Sentiment Finch Therapeutics Group Neutral Bon Natural Life Positive Which has more risk & volatility, FNCH or BON? Finch Therapeutics Group has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.47, suggesting that its share price is 147% less volatile than the S&P 500. Is FNCH or BON more profitable? Bon Natural Life's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.Company Net Margins Return on Equity Return on Assets Finch Therapeutics GroupN/A -69.14% -26.92% Bon Natural Life N/A N/A N/A Do insiders & institutionals believe in FNCH or BON? 21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable earnings & valuation, FNCH or BON? Bon Natural Life has higher revenue and earnings than Finch Therapeutics Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFinch Therapeutics Group$110K189.80-$74.75M-$8.82-1.47Bon Natural Life$23.84M0.01$400KN/AN/A SummaryBon Natural Life beats Finch Therapeutics Group on 6 of the 11 factors compared between the two stocks. Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeMedicinals & botanicals IndustryDiscretionary SectorNYSE ExchangeMarket Cap$351,000.00$1.19B$7.86B$19.29BDividend YieldN/AN/A3.25%3.83%P/E RatioN/A11.1615.1134.52Price / Sales0.018.428.0134.82Price / Cash0.7810.4016.3717.51Price / Book0.061.514.774.69Net Income$400,000.00-$56.07M$257.85M$1.02B7 Day Performance31.66%2.66%-1.44%-2.43%1 Month Performance43.59%10.79%6.47%6.27%1 Year Performance-97.13%-33.73%-1.86%5.78% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural LifeN/A$2.10+50.0%N/A-97.3%$351,000.00$23.84M0.00100News CoverageGap UpHigh Trading VolumeFNCHFinch Therapeutics GroupN/A$13.48+1.7%N/A+510.3%$21.65M$110,000.00-1.53190Gap DownSLGLSol-Gel Technologies2.1542 of 5 stars$7.72+3.3%$50.00+547.7%-2.7%$21.51M$11.54M-22.7150News CoverageOVIDOvid Therapeutics4.1688 of 5 stars$0.30-0.6%$3.03+907.4%-91.1%$21.41M$548,000.00-0.6460Gap UpQTTBQ32 Bio2.1024 of 5 stars$1.74-1.7%$24.71+1,320.4%-94.5%$21.23M$-6,651,000.00-0.1239LGVNLongeveron3.2579 of 5 stars$1.40-1.4%$8.67+519.0%+18.5%$20.90M$2.23M-0.2220News CoverageAnalyst RevisionNAIINatural Alternatives International0.5454 of 5 stars$3.31+1.8%N/A-49.4%$20.52M$121.85M-2.57290Analyst ForecastGap UpCGTXCognition Therapeutics2.5281 of 5 stars$0.33+1.5%$6.13+1,756.1%-88.0%$20.46MN/A-0.3420DRRXDURECT0.1802 of 5 stars$0.65+3.1%N/A-55.8%$20.17M$2.03M-1.0780News CoverageAnalyst ForecastGap DownHigh Trading VolumeELEVElevation Oncology2.9034 of 5 stars$0.34+20.4%$3.39+895.8%-91.6%$20.14MN/A-0.4140Negative NewsCMMBChemomab Therapeutics3.3008 of 5 stars$1.39+1.5%$8.50+511.5%+61.9%$19.96MN/A-1.3920 Related Companies and Tools Related Companies Finch Therapeutics Group Competitors Sol-Gel Technologies Competitors Ovid Therapeutics Competitors Q32 Bio Competitors Longeveron Competitors Natural Alternatives International Competitors Cognition Therapeutics Competitors DURECT Competitors Elevation Oncology Competitors Chemomab Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BON) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BON Stock Free BON Stock Alerts